As announced by Chugai Pharmaceutical Co., Ltd. on May 11, 2017 in the “Announcement of a Lawsuit Filed against Chugai,” a lawsuit was filed by Baxalta against Chugai and Genentech, Inc., a member of the Roche group in the United States District Court for the District of Delaware.  Plaintiffs filed a stipulation of dismissal with prejudice regarding plaintiffs’ claims against Chugai with the Court on September 13, 2018, and the Court issued an Order Dismissing Chugai from this lawsuit on September 19, 2018 (local time). The lawsuit against Genentech remains pending in the U.S.

The overview of the notice of dismissal is as follows:

1. History

   Filing of a lawsuit by Baxalta	May 4, 2017
   Filing of a motion to dismiss by Chugai	September 13, 2017
   Filing of a notice of dismissal by Baxalta	September 13, 2018
   Court Order dismissing Chugai	September 19, 2018

2. Circumstances from the Filing of the Lawsuit to the Dismissal
   Baxalta alleges that HEMLIBRA^® (US generic name: emicizumab-kxwh), a drug for the treatment of hemophilia A developed by Chugai, for people with hemophilia A, infringes US Patent Number 7,033,590. Thus, Baxalta filed a lawsuit against Chugai and Genentech requesting relief including an injunction enjoining manufacturing, using, offering to sell, or selling HEMLIBRA within the US, or importing HEMLIBRA into the US. Chugai filed its motion to dismiss Baxalta’s complaint for lack of personal jurisdiction. Baxalta filed a stipulation dismissing  its claims against Chugai with prejudice, and the Court issued an order adopting the proposed dismissal of Chugai from this lawsuit.
3. Plaintiffs

   (1) Name:	Baxalta Incorporated Baxalta GmbH
   (2) Address:	1200 Lakeside Drive Bannockburn, IL 60015, USA Thurganerstrasse 130 Glattpark Opfikon 8152, Switzerland

4. Prospects
   No change is expected to be made to Chugai’s financial prospects.

Trademarks used or mentioned in this release are protected by law.